Just In: Boston Scientific Acquires Nalu Medical for $533 Million

MARLBOROUGH, Mass., Oct. 17, 2025 — Boston Scientific has acquired Nalu Medical, Inc., for approximately $533 million in cash. The acquisition brings Nalu’s peripheral nerve stimulation, or PNS, technology into Boston Scientific’s portfolio, expanding treatment options for patients with chronic pain. The device addresses persistent pain in the shoulder, lower back, and knee. The miniaturized, battery-free implantable pulse generator operates wirelessly through an external disc and is controlled via a smartphone application.

Designed for patient convenience and minimal invasiveness, Nalu’s PNS system can be implanted in an outpatient setting, allowing patients to maintain mobility and daily routines without interruption. FDA clearance in 2019 confirmed its clinical performance. In late-stage trials, 79% of patients reported an average pain reduction of 64% at six months, demonstrating its potential for patients who have limited alternatives.

The acquisition highlights Boston Scientific’s commitment to addressing chronic pain, a condition affecting millions worldwide. Incorporating Nalu’s technology broadens the company’s portfolio while providing physicians with additional tools to manage complex pain cases effectively. This move reflects a strategic focus on next-generation neurostimulation therapies and minimally invasive treatment options.

How Does This Acquisition Benefit Boston Scientific?

Boston Scientific gains an innovative PNS therapy that complements existing treatments, including spinal cord stimulation, basivertebral nerve ablation, and radiofrequency ablation. Integration of Nalu’s technology expands options for patients and clinicians addressing chronic pain, ensuring a more comprehensive approach to treatment.

The acquisition is expected to close in the first half of 2026, subject to customary conditions. Analysts project minimal impact on Boston Scientific’s adjusted earnings per share in 2026, with modest accretion in 2027 and increasing benefits in subsequent years. The company anticipates synergies in distribution, training, and marketing, allowing Nalu’s devices to reach a broader patient base more rapidly.

What Sets Nalu’s Technology Apart?

Compact Design and Wireless Operation: Nalu’s device features a small, patient-friendly form factor and smartphone-based control. Its wireless operation eliminates bulky batteries, enhancing comfort and ease of use. Patients benefit from a minimally disruptive therapy, improving adherence and satisfaction.

Proven Clinical Results: Clinical trials support the device’s effectiveness. In the COMFORT study, 87% of participants experienced more than 50% pain reduction at 12 months. Real-world data from over 2,000 patients indicates a 94% rate of clinically meaningful improvement, demonstrating consistent outcomes in diverse patient populations.

Strategic Implications for Boston Scientific

The acquisition strengthens Boston Scientific’s position in chronic pain management. Nalu’s technology enhances competitive advantage while broadening therapeutic options. It reinforces the company’s commitment to patient-centered care and a full spectrum of chronic pain solutions, from spinal cord stimulation to peripheral nerve therapies.

Nalu’s sales are projected to exceed $60 million in 2025, with growth of more than 25% expected in 2026. Beyond revenue, the integration highlights Boston Scientific’s focus on innovation, next-generation therapy development, and global market reach. The move also reflects a broader industry trend toward minimally invasive, technologically advanced pain solutions, positioning Boston Scientific as a leader in this space.

Boston Scientific’s acquisition of Nalu Medical marks a significant milestone in chronic pain management. Incorporating Nalu’s neurostimulation technology broadens treatment options, supports clinical excellence, and positions the company at the forefront of next-generation pain therapies. The strategic move demonstrates the company’s dedication to innovation, patient outcomes, and the continued growth of its neuromodulation portfolio.

The integration of minimally invasive, wireless technology is set to transform patient care and expand the range of therapeutic options available to clinicians.

Inputs from Diana Chou

Editing by David Ryder